Erlotinib Online

How and where to order Erlotinib HCl (Tarceva) 150 mg tablets online on NCCME website:

Prices:from $34.30 per pill
Discount:5% coupon: 5OFF
Forms:Tarceva (Erlotinib Hydrochloride) 150 mg tablets
Quantity:30 bottles
Type:Erlotinib brand, Erlonat brand, Tarceva generic
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Erlotinib (trade names include Tarceva, Erlocip, Erlonat, Zyceva) is an anti-cancer medication from protein kinase inhibitors pharmacological group. This medicine is used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works as an epidermal growth factor receptor inhibitor (EGFR inhibitor).

Tarceva (Erlotinib Hydrochloride) tablets 150 mg

Related medications:

  • Afatinib (Gilotrif)
  • Alectinib (Alecensa)
  • Cabozantinib (Cabometyx, Cometriq)
  • Crizotinib (Xalkori)
  • Dabrafenib (Tafinlar)
  • Entrectinib (Rozlytrek)
  • Everolimus (Zortress, Certican)
  • Icotinib (Conmana)
  • Imatinib (Gleevec)
  • Lapatinib (Tykerb, Tyverb)
  • Lenvatinib (Lenvima, Lenvanix)
  • Midostaurin (Rydapt)
  • Neratinib (Nerlynx)
  • Nilotinib (Tasigna)
  • Palbociclib (Ibrance)
  • Quizartinib (Vanflyta)
  • Ribociclib (Kisqali)
  • Ridaforolimus (Deforolimus)
  • Sorafenib (Nexavar)
  • Sunitinib (Sutent)

    Pharmacological and medical categories:

  • Anti cancer drugs
  • Antineoplastic medicines
  • Cytostatic agents
  • Epidermal growth factor receptor tyrosine kinase (EGFR) inhibitors
  • NSCLC treatment medications
  • Oncological treatment
  • Pancreatic cancer therapy

    ATC codes:

  • L - Antineoplastic and immunomodulating agents
  • L01 - Antineoplastic agents
  • L01X - Other antineoplastic agents
  • L01XE - Protein kinase inhibitors
  • L01XE03 - Erlotinib

    ICD-10 codes:

  • Malignant neoplasm of pancreas - C25
  • Malignant neoplasm of bronchus and lung - C34

    Indications and usage:

  • Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
  • Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
  • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.



    Dosage and administration:

  • The dose for NSCLC is 150 mg/day.
  • The dose for pancreatic cancer is 100 mg/day.
  • All doses of Tarceva should be taken on an empty stomach at least one hour before or two hours after food.
  • Reduce in 50 mg decrements, when necessary.

    Dosage forms and strengths:

    Tarceva (Erlotinib Hydrochloride) film-coated tablets for oral use: 25 mg, 100 mg, and 150 mg.


    Withhold erlotinib in patients with an overdose or suspected overdose and institute symptomatic treatment.

    Warnings and precautions:

  • Interstitial lung disease (ILD): Occurs in 1.1% of patients. Withhold Tarceva for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue Erlotinib if ILD is diagnosed.
  • Renal failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold Tarceva for severe renaltoxicity.
  • Hepatotoxicity: Occurs with or without hepatic impairment, including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or discontinue Tarceva (Erlotinib Hydrochloride) for severe or worsening liver tests.
  • Gastrointestinal perforations: Discontinue this drug.
  • Bullous and exfoliative skin disorders: Discontinue Tarceva.
  • Cerebrovascular accident (CVA): The risk of CVA is increased in patients with pancreatic cancer.
  • Microangiopathic hemolytic anemia (MAHA): The risk of MAHA is increased in patients with pancreatic cancer.
  • Ocular disorders: Discontinue this medication for corneal perforation, ulceration or persistent severe keratitis.
  • Hemorrhage in patients taking warfarin: Regularly monitor INR in patients taking warfarin or other coumarin-derivative anticoagulants.
  • Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

    Drug interactions:

  • CYP3A4 inhibitors or a combined CYP3A4 and CYP1A2 inhibitor increase erlotinib plasma concentrations. Avoid concomitant use. If not possible, reduce Tarceva dose.
  • CYP3A4 inducers decrease erlotinib plasma concentrations. Avoid concomitant use. If not possible, increase Erlotinib dose.
  • Cigarette smoking and CYP1A2 inducers decrease erlotinib plasma concentrations. Avoid concomitant use. If not possible, increase Tarceva dose.
  • Drugs that increase gastric pH decrease erlotinib plasma concentrations. For proton pump inhibitors avoid concomitant use if possible. For H-2 receptor antagonists, take this medicine 10 hours after H-2 receptor antagonist dosing. For use with antacids, separate dosing by several hours.

    Use in specific populations:

    Lactation: Do not breastfeed.

    Adverse reactions, side effects:

  • The most common adverse reactions (>20%) in maintenance treatment are rash-like events and diarrhea.
  • The most common adverse reactions (>20%) in 2nd line NSCLC are rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, infection and vomiting.
  • The most common adverse reactions (>20%) in pancreatic cancer are fatigue, rash, nausea, anorexia, diarrhea, abdominal pain, vomiting, weight decrease, infection, edema, pyrexia, constipation, bone pain, dyspnea, stomatitis and myalgia.

    Pregnancy categories:

  • C - Australia (Risk cannot be ruled out)
  • N - United States (Not classified yet)

    Salts and other forms:

  • Erlotinib Base
  • Erlotinib Hydrochloride
  • Erlotinib Mesylate

    Synonyms, international and chemical names:

  • Erlotinibe
  • Erlotinibi
  • Erlotinibum
  • Erlotynib

    Brands, generics, trade names:

  • Erlocip - Cipla
  • Erlonat - Natco Pharma
  • Erlotinib - Mylan
  • Tarceva - Roche, Astellas Pharma, Genentech, OSI Pharmaceuticals, Schwarz Pharma
  • Zyceva - Zydus pharmaceuticals


  • Erlotinib main article on Wikipedia:
  • Erlotinib compound on PubChem:
  • Erlotinib Hydrochloride compound on PubChem:
  • Erlotinib on DrugBank:
  • Erlotinib Hydrochloride on DrugBank:
  • Erlotinib FAQ on MedlinePlus (revised 03/15/2017):
  • Tarceva (Erlotinib Hydrochloride) tablets drug label info on DailyMed (revised December 12, 2018):
  • Erlotinib Hydrochloride film-coated tablets drug label info on DailyMed (revised October 25, 2019):
  • Erlotinib for sale on Pharma Doctor (revised September 2021):
  • Tarceva (Erlotinib Hydrochloride) oral tablets official prescribing and patient counseling information from the U.S. FDA (revised 10/2016):
  • Tarceva (Erlotinib Hydrochloride) tablets for oral use prescribing and patient information from Genentech pharmaceutical company (revised 10/2016):
  • Tarceva (Erlotinib) tablets official website:
  • Tarceva (Erlotinib HCl) 25 mg, 100 mg, 150 mg film-coated tablets package information leaflet on (revised November 2018):
  • Erlocip (Erlotinib, Tarceva generic) 100 mg and 150 mg tablets prescribing information from Cipla pharmaceutical company (revised July 2015):

    Revised: September 2021

    Home | About Us | Erlotinib | Flibanserin | Luliconazole | Tolvaptan | Udenafil | FAQ | Contact Us

    Copyright © 2006 - 2021 The National Commission for Certification of CME Professionals, Inc. (NCCME, NC-CME). All rights reserved.